Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

The green light means that Paxlovid – based on nirmatrelvir (formerly PF-07321332) and ritonavir – has been cleared for use in the US ahead of rival therapy molnupiravir from Merck & Co and ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

KIRKLAND — Merck Canada appoints David D. Jones as president and Managing Director, effective September 1, 2024. Jones is succeeding Marwan A. Akar, who has held the position since June 2021.

Merck reported adjusted earnings of $2.28 per share for second ... mainly Europe and Asia Pacific region. Lagevrio (molnupiravir) generated sales of $110 million in the second quarter, down 42% year ...

A month has gone by since the last earnings report for Merck (MRK). Shares have added about 3.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.